Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Why China is reluctant to ‘live with COVID’. It’s not just politics.

China is battling its worst COVID-19 outbreak since the start of the pandemic. Total case numbers have risen to 733,000 since early March, almost nine times the number in the initial wave. At the epicenter of the outbreak, infection numbers in Shanghai have remained stubbornly high despite the citywide lockdown having lasted for more than a month.

The economic costs of strictly adhering to the “zero COVID” strategy are mounting. The notable deterioration in activity data in March offered a glimpse of the growth shock, but that merely scratches the surface given that Shanghai’s lockdown started in late March. The current outbreak, combined with the Chinese government’s determination to persist with the zero-COVID policy, has turned hitting the 5.5 per cent growth target from challenging to impossible even with an aggressive stimulus package.

Source: South China Morning Post

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!